Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

RPC1063

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Ozanimod (RPC1063) is a specific and potent small molecule modulator of the sphingosine 1-phosphate receptor 1 (S1PR1) and… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Review
2017
Review
2017
Sphingosine 1-phosphate receptor (S1PR) modulators possess a unique mechanism of action in the treatment of multiple sclerosis… Expand
  • figure 1
  • figure 2
  • table 1
  • table 3
Review
2017
Review
2017
Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, involve an inappropriate immune reaction in… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Highly Cited
2016
Highly Cited
2016
Sphingosine1‐phosphate (S1P) receptors mediate multiple events including lymphocyte trafficking, cardiac function, and… Expand
Highly Cited
2016
Highly Cited
2016
BACKGROUND Ozanimod (RPC1063) is an oral agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 that induces peripheral… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
Review
2015
Review
2015
Sphingosine 1-phosphate (S1P) receptor modulators possess a unique mechanism of action as disease-modifying therapy for multiple… Expand
  • figure 1
  • figure 2
2015
2015
Digestive Disease Week (DDW) 2015 will take place in Washington, DC, from May 17 to 19. With more than 400 scientific sessions… Expand
2014
2014
OBJECTIVE: Evaluate the clinical pharmacokinetics (PK) and pharmacodynamics (PD) of RPC1063 and its metabolites. BACKGROUND… Expand
2013
2013
OBJECTIVE: Identify metabolites of RPC1063 and determine their activity in vitro and in vivo. BACKGROUND: RPC1063 is a potent… Expand